GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 14, 2024
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia June 27, 2024
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules May 21, 2024